Evidence map›Paper›PMID 42675115›Full record

ReviewNature immunology2026

Immune-mediated rheumatoid arthritis: from single-cell genomics to new therapies.

Lionel B Ivashkiv

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lionel B IvashkivResearch Institute and David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, USA. ivashkivl@hss.edu.ORCID http://orcid.org/0000-0002-9951-0646

Funding

STEROID THERAPY AND CYTOKINES IN RHEUMATIC DISEASESR01AI046712 · NIAID · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 2000 to 2025
$12.5M
CYTOKINE REGULATION OF RA SYNOVIOCYTE PHENOTYPER01AR046713 · NIAMS · HOSPITAL FOR SPECIAL SURGERY · PI IVASHKIV, LIONEL B · 1999 to 2025
$8.3M
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI046712U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01050401U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01AR046713
6 · The paper itself

Abstract

The recent application of single-cell genomics to the investigation of immune-mediated arthritis has resulted in an explosion of information, including the discovery of lymphocyte, myeloid and fibroblast cell subsets proposed to be pathogenic. A challenge in the field is how to leverage these exciting but largely descriptive and correlative datasets to gain insights into causality and mechanisms of disease. In this Perspective, I describe emerging data and discuss ideas about how spatial transcriptomics, ex vivo mechanistic and organoid studies, and improved use of animal models based on human disease data can advance the understanding of immune-mediated arthritis pathogenesis, with a focus on rheumatoid arthritis. These insights can form the basis for designing new therapeutic strategies and implementing clinical trials. The concepts and approaches described here for arthritis may have broader applicability to other tissues and immune-mediated diseases.

Indexed as

Arthritis, RheumatoidGenomicsSingle-Cell AnalysisAnimalsDisease Models, AnimalHumansSingle-Cell Gene Expression Analysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.